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Background: Achieving earlier stage diagnosis is one option for improving lung cancer outcomes in the United Kingdom. Patients
with lung cancer typically present with symptoms to general practitioners several times before referral or investigation.
Methods: We undertook a mixed methods feasibility individually randomised controlled trial (the ELCID trial) to assess the
feasibility and inform the design of a definitive, fully powered, UK-wide, Phase III trial of lowering the threshold for urgent
investigation of suspected lung cancer. Patients over 60, with a smoking history, presenting with new chest symptoms to primary
care, were eligible to be randomised to intervention (urgent chest X-ray) or usual care.
Results: The trial design and materials were acceptable to GPs and patients. We randomised 255 patients from 22 practices,
although the proportion of eligible patients who participated was lower than expected. Survey responses (89%), and the fidelity of
the intervention (82% patients X-rayed within 3 weeks) were good. There was slightly higher anxiety and depression in the control
arm in participants aged 475. Three patients (1.2%) were diagnosed with lung cancer.
Conclusions: We have demonstrated the feasibility of individually randomising patients at higher risk of lung cancer, to a trial
offering urgent investigation or usual care.
There were 44 888 new cases of lung cancer in the United Kingdom
In 2012, making it the second most common cancer, representing
13% of all new cancers (Cancer Research UK, 2015). In the same
year, there were 35 371 deaths; 10-year survival is 5%. Options for
improving outcomes in lung cancer are either by diagnosing at an
earlier stage, potentially allowing curative surgery, or by improving
treatments. Options for earlier stage diagnosis include: screening
programmes with low-dose CT for people at high risk (National
Lung Screening Trial Research Team, 2013); targeted public
awareness campaigns to encourage people with symptoms to
*Correspondence: Professor RD Neal; E-mail: r.d.neal@leeds.ac.uk
Received 16 May 2016; revised 31 October 2016; accepted 16 November 2016; published online 10 January 2017
& 2017 Cancer Research UK. All rights reserved 0007 – 0920/17
FULL PAPER
Keywords: lung cancer; early diagnosis; health economics; chest X-ray; NICE; RCT; symptoms; cough
British Journal of Cancer (2017) 116, 293–302 | doi: 10.1038/bjc.2016.414
www.bjcancer.com |DOI:10.1038/bjc.2016.414 293
present earlier (Athey et al, 2012; Ironmonger et al, 2015); GPs
investigating higher risk patients with symptoms more quickly
(as in this trial); allowing GPs access to low-dose CT (Guldbrandt
et al, 2014); and the development of predictive biomarkers. There
is systematic review evidence that, for lung cancer, the evidence
that timelier diagnosis is associated with better outcomes is
equivocal (Neal et al, 2015a); however the higher quality studies
reported in this review do show an association (Brocken et al, 2012;
Murai et al, 2012; Tørring et al, 2013), suggesting that there is
merit in expediting the diagnosis of people presenting
symptomatically.
The diagnosis of lung cancer in general practice can be complex
and difficult (Neal et al, 2015b) and can therefore be ‘easily missed’
(Neal et al, 2014). The symptom signature of lung cancer is
variable (Shim et al, 2014), and many patients consult with their
general practitioner several times before referral or investigation
(Lyratzopoulos et al, 2012; Birt et al, 2014). In England and Wales,
diagnostic activity for cancer is guided by the National Institute for
Health and Care Excellence (NICE); their 2005 guidelines (NICE,
2005) were updated in 2015 (NICE, 2015). In this trial we
hypothesised that an intervention to lower the NICE symptom
threshold for investigation ‘extra-NICE’ may improve clinical
outcomes in lung cancer and the cost-effectiveness of lung cancer
diagnosis. Our definition of ‘extra-NICE’ (as compared with NICE,
2005 as these were in place at the time of the trial) was urgent
referral for a chest X-ray for patients aged 60 years or over
presenting in general practice with a new or altered cough of any
duration, increased breathlessness, or wheezing (whether or not
associated with purulent sputum), and who were either current
smokers or ex-smokers with a 10 or more pack-years of smoking.
At the time of the trial, the NICE (2005) guidelines recommended
chest X-ray after 3 weeks of symptoms in these patients. The new
guidelines (NICE, 2015) were published after the trial closed,
recommend chest X-ray within 2 weeks in people aged 40 and over
if they have two or more of selected unexplained symptoms
(cough, fatigue, shortness of breath, chest pain, weight loss,
appetite loss), or one of these if they have ever smoked.
This trial aimed to assess the feasibility and inform the design
of a definitive, fully powered, UK-wide, Phase III clinical trial of
a change to the NICE guidelines for urgent investigation of
suspected lung cancer in patients aged over 60. In particular, this
paper reports the results and lessons drawn from the develop-
ment work and the mixed methods feasibility trial that set out to
determine: the acceptability of trial design and materials; the
training and recruitment of practices; the recruitment and
randomisation of patients; appropriate methods for collection of
wider clinical and health economics data in a full trial; and the
views of participants and non-participants on recruitment and
randomisation, and health-care professionals. The trial utilises a
combination of workshop, health economics, quality of life,
qualitative, and quantitative methods, examining the feasibility
of a full trial.
MATERIALS AND METHODS
ELCID (Early Lung Cancer Investigation and Diagnosis) was a
randomised, parallel group, unblinded, feasibility trial carried out
in general practices in Wales and Yorkshire. A Working Group was
formed before recruitment and randomisation with key stake-
holders. It aimed to identify the best way to train GPs to identify
and recruit eligible patients into the trial, and to identify the most
effective method of presenting the trial (and randomisation) to
patients. The outputs from this Working Group informed some of
the practicalities of recruiting practices and participants and
maximising data collection.
Study design, randomisation, sample size considerations, data
collection procedures, and planned statistical methods have been
published elsewhere (Hurt et al, 2013). Briefly, patients aged over
60 years, who were either smokers or ex-smokers with 10 or more
pack-years of smoking history, and who presented at a general
practice with a new or altered cough of any duration, or increased
breathlessness or wheezing (whether or not associated with
purulent sputum), were invited to participate. Patients who
qualified for urgent referral for chest X-ray under NICE, 2005
guidelines, or who had had a chest X-ray or CT scan of the chest in
the last 3 months, or who needed a chest X-ray within next 3
weeks, or who had previously been diagnosed with cancer and who
had a life expectancy of less than 1 year, were ineligible.
Initially, all general practices in the four Health Boards in South
east Wales were invited to participate in the trial. In addition, six
practices in Yorkshire were recruited by the local research network
(as were a further six practices from north Wales halfway through
the trial – see later). Patients were identified either at presentation
or, in some practices where resources existed to do so, by looking
through the records of the previous week’s consultations. Patients
identified at presentation were introduced to the trial and invited
to consent or given a future appointment at which eligibility could
be confirmed and consent could be taken. Patients identified
through medical records were invited to make an appointment to
discuss the trial, eligibility, and consent.
The trial aimed to assess:
 Key design parameters (prevalence of ‘extra-NICE’ symptoms,
trial consent rate, and lung cancer rate).
 Whether the intervention caused increased anxiety or depression
 The outcomes of the chest X-rays.
 The acceptability of trial procedures to participants and
recruiters.
 The best ways of collecting trial data (patient recall, GP records,
and routine data sets).
The study was developed on behalf of the NCRI Primary Care
Clinical Studies Group, funded by the UK National Awareness and
Early Diagnosis Initiative (NAEDI), sponsored by Bangor
University, and coordinated by the Wales Cancer Trials Unit and
South East Wales Trials Unit at Cardiff University. The study was
approved by a UK multicentre ethics committee and carried out in
accordance to the declaration of Helsinki and all UK regulatory
requirements.
Those who were eligible and provided written informed consent
were then individually randomised (1 : 1) to either an urgent chest
X-ray or usual care (NICE, 2005). Patients were randomised and
informed of their allocation before being given a suite of
questionnaires to complete (Box 1). The same questionnaires were
posted to patients 2 months later. Twelve months after
randomisation, general practices were contacted to provide
follow-up information on the outcomes of any chest X-rays,
health service resource use, and clinical outcomes. Data from the
Welsh Cancer Intelligence and Surveillance Unit (WCISU) were
used to verify the lung cancer data provided by general practices at
12 months (Wales only). The CTU staff maintained regular contact
Box 1. Post randomisation and 2 months questionnaires
Hospital Anxiety and Depression Scale (HADS) (Zigmond and Snaith, 1983).
Client Service Receipt Inventory (CSRI) (Beecham and Knapp, 1999; Ridyard
and Hughes, 2010; Ridyard et al, 2012).
ICEpop CAPability measure for Older people (ICECAP-O) (Coast et al, 2008).
EuroQol 5 Dimensional Health State Questionnaire (EQ-5D-3L) (EuroQol
Group, 1990; EuroQoL, 2015).
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with the practices throughout the study. Full excess treatment and
service support costs were provided. In order to incentivise
practices further, there were occasional prizes for practices for best
or most improved recruitment.
Randomisation. Randomisation took place centrally via the
Bristol Randomised Trials Collaboration using either an automated
telephone or a secure online service. Participants were randomised
using minimisation with a random element (80 : 20) stratified by
general practice, age (o75, X75), and chronic obstructive
pulmonary disease diagnosis.
Statistical analysis. The sample size was based on modelling work
using the CAPER-lung database, which contains all primary-care
consultations, symptoms, and investigations in the 2 years before
diagnosis for a 5-year cohort of 247 lung cancer cases (Hamilton
et al, 2005; Barrett and Hamilton, 2008). We estimated that 0.77%
of practice patients would be eligible for the trial in a year, that as
many as 70% of those may be recruited, and of those recruited,
2.4% would develop lung cancer (Hurt et al, 2013). The trial aimed
to recruit a sample size of 386 for reasonable precision around
these estimates: the proportion of eligible patients in United
Kingdom practices per year (0.77%, 95% confidence intervals (CIs):
0.70–0.83%) and of those recruited, the proportion developing lung
cancer within 12 months (2.4%, 95% CIs: 0.9–3.9%).
Data were analysed using the STATA SE 14 statistical package
(StataCorp LP, 4905 Lakeway Drive, TX, USA) according to
intention-to-treat. All analyses were pre-specified a priori. When
determining the lung cancer data (proportion diagnosed, stage of
lung cancer, performance status, and radical treatment) the
WCISU data set was taken as correct if it differed from the
general practice data. Recruitment rates were assessed by: Primary
Care Research Incentive Scheme (PiCRIS) level – a Welsh
Governmental funding and support scheme for general practices
(NHS Wales, 2014); practice size; and months open to recruitment.
We compared the completion rates of all questionnaires by trial
arm, using w2-tests. Subgroup analyses of completion of all
questionnaires was also assessed by age (o75 vs X75 years),
gender, post-randomisation anxiety, ethnicity, and smoking status.
Post-randomisation anxiety and depression median scores were
compared using Mann–Whitney tests. Subgroup analyses of anxiety
and depression by age (o75 andX75 years), gender, and smoking
status (current or ex-smoker) using Mann–Whitney tests were also
performed. Differences in anxiety/depression scores between arms at
2 months post randomisation were assessed using multiple linear
regression, with treatment arm and post-randomisation score as
covariates in a base model. Subgroup analyses were performed by:
(a) repeating this model by age (o75 or X75), gender, and
smoking history (current or ex).
(b) adding age, gender, or smoking history to the base model
together with an interaction with treatment arm.
To ensure the validity of the linear regressions, checks were
made for evidence of non-normality of residuals using Shapiro–
Wilk tests and kernel density, normal probability and normal
quantile plots, and heteroscedasticity using residuals vs. fits plots.
No adjustment was made for multiple testing.
Health economics. Health economic data were collected post
randomisation and at 2 months as shown in Box 1. The health
service use information from the patients was compared with data
about resource use collected from the GPs to ascertain the most
appropriate method of capturing these data in the full trial. Data
were analysed using the IBM SPSS Statistics Version 22 statistical
package (IBM Corp., Armonk, NY, USA). The agreement analysis
examined the level of agreement between the patient and GP as
information sources. Data included: investigations (‘Other’ chest
X-ray (i.e., chest X-ray not including the one received on the ELCID
trial as part of the intervention), CT scan, MRI scan, and PET-CT
scan) performed on patients by 2 months. The Kappa (k) statistic
was employed to test investigation use agreement (Shoukri, 2015).
The Landis and Koch standard scales for strength of agreement for
the k coefficient were applied (Landis and Koch, 1977).
RESULTS
Practice and patient recruitment. The acceptability of the trial
design was determined by the Working Group, and was reflected in
the successful initial recruitment in Wales and Yorkshire. Twenty-
eight practices were recruited from Wales and six from Yorkshire.
However, three Welsh sites withdrew from the study without
recruiting a participant. Twenty-two of the remaining 31 practices
randomised 255 participants between 8 November 2012 and
9 April 2014. The CONSORT flow diagram is shown in Figure 1.
The acceptability of the trial design was determined by the
Working Group, and was reflected in the successful initial
recruitment in Wales and Yorkshire. A total of 28 practices were
initially recruited (22 South east Wales and 6 in Yorkshire), of
which three later withdrew, without recruiting any patients.
Halfway through the trial, an additional six practices were recruited
from north Wales by the local research network to boost
recruitment. Twenty-two of the remaining 31 practices randomised
255 participants between 8 November 2012 and 9 April 2014. Nine
sites failed to recruit a single participant. Those that failed to
recruit cited lack of resources or lack of eligible patients as reasons.
The CONSORT flow diagram is shown in Figure 1.
Recruitment screening log data were poorly completed gen-
erally, but two practices provided reliable data, based on agreement
between participation recorded on screening logs and central
randomisation data. From these two practices, the prevalence of
the trial eligibility criteria was calculated as 0.75% of practice
registrations per year (214 eligible people per year from a combined
registered population of 28 502; 95% CI 0.65–0.86%). In addition,
from these two sites, the proportion of eligible patients who agreed
to participate was 74 out of 223 (33.2%; 95% CI 27.0–39.8%).
The recruitment of participants by practice size, known research
activity (PiCRIS scheme – Welsh practices only), and number of
months open to recruitment is shown in Table 1. This shows that:
practice size had little overall effect on the number of randomised
patients per 1000 per year; the PiCRIS level of the practice had little
effect on the number of randomised patients per 1000 per year,
other than ‘sessional’ (the highest level of participation) practices
having a higher randomisation rate; and that practices which were
open to recruitment for shorter periods of time had a higher rate of
recruitment.
Baseline comparability between the groups. The breakdown of
the variables, overall, and by trial arm, are shown in Table 2. This
shows that the demographics (gender, age, ethnicity, duration and
highest level of education, and economic situation), presenting
symptoms, pre-existing co-morbidity, and numbers of recent chest
X-rays had similar distributions in each trial arm.
Fidelity of the intervention. About 113 out of 127 (89.0%)
patients in the intervention arm received a total of 148 chest X-rays
within 12 months. Of these, 88 patients (69.3%) had their first
X-ray within 7 days, 100 (78.7%) within 14 days, and 104 (81.9%)
within 21 days. Forty-three out of 128 (33.6%) participants in the
control arm also received a total of 50 chest X-rays within 12
months. Of these, 3 patients (2.3%) had their first X-ray within 7
days, 10 (7.8%) within 14 days, and 13 (10.2%) within 21 days. The
median times to chest X-ray in the intervention and control
groups were 3 days (interquartile range (IQR) 1–7), and 71 days
(IQR 17–233, respectively). In the intervention arm, 10 (7.9%)
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patients had repeat chest X-rays within 3 months (8 had 1 repeat, 2
had 2 repeats witho3 months between each). In the control arm,
3 (2.8%) patients had repeat chest X-rays (1 patient had 1 repeat, 2
had 2 repeats with o3 months between each).
Significant adverse events. Three patients in the control arm died,
one due to lung cancer (52 days post randomisation), one due to
myocardial infarction (178 days post randomisation), and one due to
cardiac arrest (216 days post randomisation). One patient in the
Table 1. Breakdown of recruitment by practice size, known research activity (PiCRIS scheme), number of months open to
recruitment
Participants randomised
Number of practices Mean number of patients per practice (s.d.) N Per 1000 per year
Practice size (patients)
1st quartile up to 5252 8 3906.4 (1392.9) 35 0.92
2nd quartile 5253–8301 7 7221.9 (783.6) 66 1.04
3rd quartile 8302–12 037 8 9911.4 (1037.2) 36 0.38
4th quartile 12 038–21 433 8 15 128.6 (3140.0) 118 1.18
Research activity
PiCRIS level 1 4 8724 (3656.1) 19 0.45
PiCRIS level 2 4 10 786.5 (4640.6) 19 0.46
Sessional 6 12 877.5 (5409.0) 154 2.15
Nonea 17 7459.8 (3840.8) 63 0.41
Months open
1st quartile up to 9.3 9 9693 (5789.5) 94 1.48
2nd quartile 49.3–14.2 9 8166.6 (3090.5) 66 0.77
3rd quartile 414.2–16.2 6 9645.7 (5887.9) 55 0.71
4th quartile 416.2–18.2 7 9073.4 (4074.8) 40 0.42
Abbreviation: PiCRIS¼Primary Care Research Incentive Scheme.
aIncludes English centres where PiCRIS funding is not available.
Assessed for eligibility (n = 298(1027))*
Not meeting inclusion criteria (n = 75(259))*
Lost to follow-up 
No 12 month CRF returned (n = 5) 
Allocated to control (n = 128)
Received allocated intervention (n = 126)
Referred for urgent chest x-ray in error
(n = 2) 
Lost to follow-up 
No 12 month CRF returned (n = 7)
Allocated to intervention (n = 127)
Received allocated intervention
(referred for x-ray) (n = 127)
Randomised (n = 255)
Did not participate (n = 149(513))*
Patient not interested (n = 59(203))
Unable to contact patient (n = 32(110))
Not enough time to discuss trial with patient (n = 15(52))
Referred patient for urgent imaging (n = 12(41))
Patient too ill (n = 11(38))
Patient does not want to travel (n = 7(24))
Other (n = 13(45))
Eligible patients (n = 223(768))*
Figure 1. Consort diagram. *Box shows actual numbers from complete screening data from two sites. Figure in square brackets is the overall
prediction using the numbers from the two sites as an estimate to predict likely screening at other sites that recruited at least one patient.
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intervention arm died, due to lung cancer; time to death was 95 days.
None of these events were thought to be related to study procedures.
Survey responses and Hospital Anxiety and Depression Scores.
Survey responses are shown in Table 3. This shows that
completion of all tools post randomisation was good (89.4%),
and equal in both the groups. Completion of tools at 2 months
was also similar between the two groups, with just less than two-
thirds completion. There was no evidence for differences in
completion between arms within subgroups based on age, sex,
post-randomisation anxiety, or smoking history (data not
presented). Hospital Anxiety and Depression Scores are also
presented in Table 3. There was no evidence of a difference in
post-randomisation anxiety scores between trial arms (median
(IQR): 6 (3–8) in control vs 5 (3–9) in intervention, z¼ 0.32;
P¼ 0.75) or between arms by subgroups based on age, sex, or
smoking history (PX0.35). Similarly, there was no evidence for a
difference in post-randomisation depression between arms
(median (IQR): 6 (3–8) in control vs 5 (3–9) in intervention,
z¼  0.12; P¼ 0.91) or between arms by subgroups based on
age, sex, or smoking history (PX0.56). The 2-month results
presented in Table 3 suggest no difference in either anxiety or
depression between trials arms except when performing
subgroup analyses using age. For both anxiety and depression,
the model that included age as a covariate had significant age-
trial arm interaction terms (P¼ 0.02 and 0.05, respectively).
Table 2. Baseline demographics, co-morbidity, symptoms, and previous chest X-rays of trial participants
Control Intervention Overall
n (%) n (%) N (%)
Randomised – n 128 50.2 127 49.8 255 100.0
Gender
Male 64 50.0 66 52.0 130 51.0
Female 64 50.0 61 48.0 125 49.0
Age
Median (IQR) 67.3 (64.5–72.8) 67.9 (64.3–73.2) 67.5 (64.3–73.2)
X75 years old 23 18.0 26 20.5 49 19.2
o75 105 101 206
Identification of eligibility
Routine consultation 102 79.7 101 79.5 203 79.6
COPD clinic 1 0.8 3 2.4 4 1.6
Review of patient notes 25 19.5 23 18.1 48 18.8
Ethnicity
White 127 99.2 126 99.2 253 99.2
Other 0 0.0 1 0.8 1 0.4
Missing 1 0.8 0 0.0 1 0.4
Years of f/t education from age 5
Median (IQR) 10 (10–11.5) 10 (10–11) 10 (10–11)
Missing 0 1 1
Highest education level
University 12 9.4 6 4.7 18 7.1
Professional training 25 19.5 24 18.9 49 19.2
Secondary school 86 67.2 93 73.2 179 70.2
Did not attend secondary school 5 3.9 3 2.4 8 3.1
Missing 0 0.0 1 0.8 1 0.4
Economics
Find it a strain to get by 10 7.8 11 8.7 21 8.2
Have to be careful about money 44 34.4 45 35.4 89 34.9
Able to manage without much difficulty 40 31.3 41 32.3 81 31.8
Quite comfortably off 30 23.4 24 18.9 54 21.2
Prefer not to answer 4 3.1 6 4.7 10 3.9
Co-morbidity
At least one co-morbidity 61 47.7 76 59.8 137 53.7
Chronic pulmonary disease 37 60.7 41 53.9 78 56.9
Median Charlson score (IQR) 3 (2–4) 3 (2–4) 3 (2–4)
Previous CXRs in last 12 months
Had one 22 17.2 21 16.5 43 16.9
Not had one 106 82.8 106 83.5 212 83.1
Smoking history
Current smoker 62 48.4 59 46.5 121 47.5
Ex-smoker 66 51.6 68 53.5 134 52.5
Pack-years – median (IQR) 30 (20–45) 31 (20–45) 3 (20–45)
Presenting symptoms
Cough only 35 27.3 38 29.9 73 28.6
Coughþother symptoms 60 46.9 60 47.2 120 47.1
Breathlessness ± others 7 5.5 3 2.4 10 3.9
Missing 26 20.3 26 20.5 52 20.4
Abbreviations: COPD¼ chronic obstructive pulmonary disease; CXR¼Chest X-ray; IQR¼ interquartile range.
No missing data except where stated.
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There was a significantly higher anxiety (median (IQR): 7.5
(4.5–9) vs 4 (3–7), t¼  2.97; P¼ 0.006) and depression
(7.5 (4.5–9) vs 4 (3–7), t¼  2.67; P¼ 0.013) score in the
control arm in the X75 age group although the number of
participants in this subgroup was small (n¼ 33).
Chest X-ray outcomes, cancer diagnoses, other diagnostic
investigations, and other diagnoses. Table 4 and Figure 2 show
the outcomes of the chest X-rays. There were more normal results in
the intervention arm (105 (70.9%) vs 25 (50%)) but more patients
were found to have at least one abnormality in the intervention arm
(31 (25.8%) vs 20 (16.3%)). In the intervention arm, four chest X-rays
from three participants were suspicious of lung cancer (3 of which led
to CT scans within 3 weeks of X-ray, 2 of which led to a diagnosis of
lung cancer) compared with one in the control arm (which led to a
diagnosis of lung cancer within 34 days of randomisation without
CT scan); 20 days of chest X-ray. Data from WCISU confirmed the
three lung cancer diagnoses reported from primary care. In the
intervention arm, one was stage IA, adenocarcinoma, WHO
performance status 0, diagnosis 58 days post randomisation, and
the participant received radical treatment. The other was stage III,
missing tumour type, performance status 3, diagnosis 80 days post
randomisation, and the participant received no radical treatment. In
the control arm, this was a small cell tumour, stage 4 at diagnosis,
performance status 2, diagnosis 39 days post randomisation and the
participant received no radical treatment. Thus, 3 out of 256, that is,
1.2% (95% CIs: 0.2–3.4%) of trial participants were diagnosed with
lung cancer. A flow chart showing pathways to other outcomes from
normal and abnormal chest X-rays, including further investigations
for both trial arms is shown in Figure 2.
Exploration of the most appropriate measure of collecting
health resource use data – agreement analysis results. Table 5
shows the results of agreement between the resource use data self-
reported by the patients and the resource use data collected routinely
from the GP records. Overall there was a high degree of agreement
between patients’ self-reported data and routine-based health-care
resource use data, with values ranging from 67.67 to 97.60%.
Agreement was the highest for PET-CT scan and lowest for ‘other’
chest X-ray. However, the strength of agreement was considerably
below average, ranging from fair agreement (k¼ 0.32, s.e. 0.18, 95%
CI  0.03–0.66) for CT scan, to slight agreement (k¼ 0.20, s.e. 0.06,
95% CI 0.08–0.31) for ‘other’ chest X-ray. No results of kappa are
presented for either MRI or PET-CT; this is because no comparison
was possible as none were reported. The full findings from the health
economics analysis will be reported elsewhere.
DISCUSSION
Summary of main findings. This feasibility trial has achieved its
targets in terms of assessing: key design parameters, impact on
Table 3. Survey response at baseline and 2 months, and Hospital Anxiety and Depression Scores – 2-month questionnaires
Control Intervention Overall
n % n % n %
v2-test statistic
(v2) v2 P-value
Baseline data returned – n (%) 128 50.2 127 49.8 255 100
Baseline questionnaires
All questionnaires 118 92.2 110 86.6 228 89.4 2.09 0.15
ICECAP 123 96.1 121 95.3 244 95.7 0.10 0.75
EQ-5D 124 96.9 123 96.9 247 96.9 o0.001 0.99
CSRI 121 94.5 111 87.4 232 91 3.95 0.05
HADS 125 97.7 122 96.1 247 96.9 0.53 0.47
2-month questionnaires
All 2-month questionnaires 82 64.1 84 66.1 166 65.1 0.12 0.73
ICECAP 84 65.6 93 73.2 177 69.4 3.02 0.22
EQ-5D 85 66.4 92 72.4 177 69.4 2.32 0.31
CSRI 82 64.1 85 66.9 167 65.5 1.33 0.51
HADS 85 66.4 92 72.4 177 69.4 2.32 0.31
HADS score from 2-month questionnaires
n Median (IQR) n median (IQR)
Linear regression
test statistic (t)a P-valuea
P-value for
interactionb
Anxiety
All patients 85 7 (4–9) 92 6 (3–9.5)  0.7 0.49
Age o75 73 7 (4–8) 71 6 (3–10) 0.3 0.76 0.02
AgeX75 12 7.5 (4.5–9) 21 4 (3–7)  2.97 0.006
Male 39 6 (3–8) 51 6 (3–8) 0.09 0.93 0.52
Female 46 7 (5–9) 41 5 (3–11)  1.01 0.32
Current smoker 40 7 (5–8) 40 6 (4–12) 0.39 0.7 0.23
Ex-smoker 45 6 (3–9) 52 5 (3–7)  1.18 0.24
Depression
All patients 85 7 (4–9) 92 6 (3–9.5)  0.59 0.56
Age o75 73 7 (4–8) 71 6 (3–10) 0.26 0.8 0.05
AgeX75 12 7.5 (4.5–9) 21 4 (3–7)  2.67 0.013
Male 39 6 (3–8) 51 6 (3–8) 0.21 0.83 0.46
Female 46 7 (5–9) 41 5 (3–11)  0.99 0.33
Current smoker 40 7 (5–8) 40 6 (4–12) 0.41 0.69 0.31
Ex-smoker 45 6 (3–9) 52 5 (3–7)  1.07 0.29
Abbreviations: CSRI¼Client Service Receipt Inventory; EQ-5D¼EuroQol 5 Dimensional Health State Questionnaire; HADS¼Hospital Anxiety and Depression Scores; ICECAP¼ ICEpop
CAPability measure for Older people; IQR¼ interquartile range
aBase model in subgroup.
bBase model plus subgroup variable plus subgroup treatment arm interaction in all patients.
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anxiety/depression, chest X-ray outcomes, the acceptability of trial
procedures, and the best ways of collecting trial data. It supports
the feasibility of conducting a Phase III trial. Our trial suggests
that the prevalence of the trial eligibility criteria was 0.75%
(95% CIs: 0.65–0.86%) of practice registrations per year, matching
our estimate in the protocol. However, the proportion of eligible
Table 4. Chest X-ray outcomes
NICE Extra-NICE
n (%) n (%)
12-month follow-up expected 125 125
CRF return 123 120
Number of patients receiving at least one chest X-ray in 12 months (n) 43 35.0 113 94.2
Time to first chest X-ray – median (range (IQR)) days (if within 12 months) 71 2–348 (17–233) 3 0–308 (1–7)
Number of chest X-rays within 12 months (n) 50 148
Normal 25 50.0 105 70.9
Suspicious of lung cancer 1 2.0 4 2.7
Missing data 0 0.0 1 0.7
Other abnormality 24 48 38 25.7
Number of participantsa with at least one abnormality (lung cancer suspected or other) 20 16.3 31 25.8
Other abnormalities diagnosis 24 38
Non-lung abnormalities
Cardiac/aortic abnormalities, for example, cardiomegaly, widened aortic root 6 25.0 14 36.8
Lung abnormalities
Suspected infection 5 20.8 5 13.2
Benign lung disease 10 41.7 12 31.6
COPD 2 8.3 2 5.3
Emphysema 1 4.2 1 2.6
Pleural plaques 0 0.0 2 5.3
No change from previous 0 0.0 2 5.3
Abbreviations: COPD¼ chronic obstructive pulmonary disease; CRF¼ case report form data; IQR¼ interquartile range; NICE¼National Institute for Health and Care Excellence.
aSome patients had more than one X-ray.
I = Intervention, C = control
Patients having a chest x-ray
(in the 12 months since
randomisation)
I = 113, C = 43
Outcome
No Lung or cardiac pathology I = 69, C = 20
Other Lung pathology
Cardiac pathology     I = 4, C = 0 
Lung Cancer I = 0, C = 0
Normal chest x-ray
I = 88 C = 23
Subsequent chest x-
ray
2nd    I = 28, C = 3 
3rd     I = 2, C = 2  
4th     I = 1, C = 0 
CT scan
I = 7 (1 had
ECG, 1 had
bronchoscopy
at same time)
C = 4  
Other Investigations
MRI I = 1
Spirometry I = 10, C = 5
MRI and spirometry I = 1, C = 0
ECG I = 2, C = 0
ECHO I = 0, C = 1
ECG and ECHO I = 4, C = 0
ECHO and angiography, I = 2 C = 0
Spirometry and bronchoscopy I = 1,
C = 0
Bronchoscopy I = 0, C = 1
ECG and spirometry I = 1, C = 1 
ECG and ambulatory cardiac
monitoring I = 0, C = 1
CT, carotid artery Doppler and ECG
I = 1, C = 0 
Immunoglobulins I = 0, C = 1
Angiography I = 1 C = 0
Abnormal 1st chest x-ray
I = 25 C = 20
Cardiac pathology
I = 8 C = 5
Lung Cancer 
I = 2 C = 1
No Lung or cardiac
pathology 
I = 9 C = 2
Other Lung pathology
I = 18*, C = 14**
*I-2 participants had both lung and
cardiac pathology (non-lung cancer)
**C-1 participant had both lung and
cardiac pathology (non-lung cancer) 
88, 23
20, 2
18, 2
10, 2
6, 1 
10, 7
5, 3 2, 2
1, 1
1, 1
8, 21, 1
3, 0
3, 2
1, 3
5, 6
4, 1
5 (1 had 2 x-rays already), 0
3, 2
6, 4
1, 0
1, 0
1, 0
1, 1
76, 21
2, 0
I = 3, C = 1
Figure 2. Flow chart showing all outcomes from chest X-rays in both the groups. I¼ Intervention, C¼ control.
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patients who agreed to participate was considerably lower than
expected (33.2%; 95% CI 27.0–39.8%), explaining our lower than
anticipated recruitment of 255 participants rather than the target
386. In addition, the trial suggests that the proportion of trial
participants who developed lung cancer was 1.2% (95% CIs:
0.2–3.4%) – this is in keeping with our a priori estimate of 2.4%.
The same three cancers identified within the practices were also
identified by WCISU. The abnormal chest X-rays undertaken in
both arms triggered further investigations, again as anticipated. We
also identified more cardiac and other lung pathologies in the
intervention than control group, although we are unsure of the
clinical significance of this. We were able to collect questionnaires
from patients’ post randomisation and at 2 months with acceptable
return rates. There was some evidence that anxiety and depression
may have been higher in the control arm in those agedX75 years.
This was a challenging feasibility trial to undertake because we
did not know at the outset whether it would be acceptable to
recruit practices and patients to a study that individually
randomised patients with possible lung cancer to quicker
diagnostic testing. We were explicit in our patient recruitment
materials that participants were at higher risk of lung cancer and
that the intervention was a test to detect lung cancer earlier. We
believe that this is the first trial that has recruited and randomised
patients in this context. Through the use of good methods and
engagement, such as a Working Group, training all relevant
practice staff, practice payments for extra time taken, research
network staff support wherever possible, use of practice databases
to identify eligible patients wherever possible, we were able to
recruit practices and participants albeit at a lower rate than
anticipated.
Discussion of the findings within the context of the literature
The acceptability of trial design and materials, the training and
recruitment of practices, and the recruitment and randomisation
of patients. The work that we put into the Working Group
enabled us to make minor changes to the trial design that made the
trial more acceptable to both practices and patients. This was
demonstrated in our success in recruitment and randomisation.
Although we thought that obtaining consent from patients may be
more difficult, we elected to use an individually randomised design
rather than a cluster design. This may have led to GPs having to
take more time to explain the trial to patients accompanied by the
administrative burden of individually randomising patients, with a
consequent diminished consent rate. However, we found little
evidence of contamination in the control arm seeking urgent chest
X-rays.
Anxiety and depression. Our finding of higher anxiety in the over
75 s in the control group fits with a Danish trial that participation
in a randomised lung screening trial was associated with negative
psychosocial consequences (Aggestrup et al, 2012).
The views of patients and recruiters. The importance of
qualitative work in feasibility studies in establishing best recruit-
ment methods has been highlighted by others (Fletcher et al, 2012;
White and Hind, 2015). We successfully engaged with patient trial
participants, patient non-participants, and recruiters from prac-
tices. The findings from this, which will be reported in full
elsewhere, will inform the design of the subsequent main trial.
Briefly, recommendations are to ensure recruiting sites are
equipped to reduce misconceptions and misunderstandings of
trial purpose, processes, and interventions when seeking consent.
There will be less emphasis on smoking in the patient-facing
materials. In terms of recruitment sites, the need for a strong point
of contact for trial promotion and knowledge of processes is
advised.
The appropriateness of methods for collection of wider clinical
and health economics data in a full trial. The 2-month
questionnaire return rates were 460% – thought to be crucial in
surveys to avoid bias from outliers (Kiess and Bloomquist, 1985).
In the agreement analysis, the percentage of agreement between
self-report data and routine-based health-care resource use data
from patients’ GP records for all four types of investigations were
generally high, and line with other studies (Ungar and Coyte, 1998;
Bhandari and Wagner, 2006). These findings suggest that self-
report of health service use over a reasonably short recall period in
this older population group seems valid. The completion rates for
the tools that we used were acceptable, and we were able to collect
useful information on presenting symptoms and co-morbidity.
Quite importantly, we did not see a difference in anxiety
and depression scores between trial arms. The fidelity of
the intervention was good, in that 82% of participants in the
intervention arm received a chest X-ray within 3 weeks. The
proportion of participants in the control arm who received a chest
X-ray was similar to what we anticipated.
Strengths and weaknesses. The main strength of the study is that
we have conducted a pragmatic feasibility individually randomised
trial in primary care, and fully tested all of the processes involved
for a full trial. The main weakness is that in the protocol we aimed
to recruit 386 participants, but we only recruited 255. This has
lowered the precision with which we can estimate the key
parameters required in designing the Phase III trial. We are also
aware that the age and smoking thresholds used in this trial are
different from some of the screening trials. Our screening log data
may not be generalisable as it was based on two practices only.
In addition the number of patients recruited per practice varied,
with two practices contributing a third of the participants.
Implications for policy, practice, and research. In summary, we
believe that we have demonstrated the feasibility of this trial design.
However, while this raises several significant challenges (Box 2), we
believe that there is a need for a trial that aims to diagnose
symptomatic lung cancer earlier. This hypothesis has been helped
Table 5. Level of agreement between self-reported data and case report form data collected from the GP records (routinely
collected data) by type of investigations use in the 2 months post baseline (n¼167)
Type of investigations CRF (þ ), SR (þ ) CRF (þ ), SR ( ) CRF ( ), SR (þ ) CRF ( ), SR ( ) Agreement (%)
‘Other’ chest X-ray, n (%) 12 (7.19) 2 (1.20) 52 (31.14) 101 (60.48) 113 (67.66)
CT scan, n (%) 2 (1.20) 1 (0.60) 7 (4.19) 157 (94.01) 159 (95.21)
MRI scan, n (%) 0 (0.00) 0 (0.00) 9 (5.39) 158 (94.61) 158 (94.61)
PET-CT scan, n (%) 0 (0.00) 0 (0.00) 4 (2.40) 163 (97.60) 163 (97.60)
Abbreviations: CT¼ computed tomography; CRF¼ case report form data; ELCID¼Early Lung Cancer Investigation and Diagnosis; GP¼general practice; MRI¼magnetic resonance imaging;
PET-CT¼positron emission tomography–computed tomography; SR¼ self-reported data. Other’ chest X-ray means additional CXR received following the CXR received on the ELCID trial as
part of the ELCID intervention. The differences reported in this table may reflect a change in wording from the original CRF, that was subsequently improved from ‘Chest X-Ray’ to ‘Chest X-Ray
(not including any received on the ELCID trial)’. CRF ( ) means that the routine data did not indicate an investigation; CRF (þ ) means that the routine data indicated an investigation; SR ( )
means that the respondent did not indicate an investigation; SR (þ ) means that the respondent indicated an investigation.
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by a recent study that has estimated the symptom lead time in
lung cancer (the duration of reported symptoms before
diagnosis) finding no relationship between duration of symp-
toms and stage (Biswas et al, 2015). The data for this study were
collected in the era before the considerable expansion of
diagnostic services for suspected cancer had occurred, and it is
possible that results in a study conducted now would differ. That
paper also reported the concept of two populations with lung
cancer who are identified in any programme of enhanced
diagnostics: those whose symptoms are caused by the cancer, and
those whose symptoms met criteria for investigation, but were
not actually caused by the cancer.
In conclusion, we have demonstrated the feasibility of recruiting
to an individually randomised controlled trial in primary care for
earlier chest X-ray for patients at higher risk of lung cancer who
present to primary care with new symptoms. We are now
developing a Phase III trial with the intention of evaluating the
effect of timelier symptomatic diagnosis on lung cancer outcomes.
While NICE guidelines have changed since we undertook the
feasibility trial, we believe that our findings will inform a trial of
very similar design; that is, individual randomisation of people at
greater risk for expedited investigation or usual care. Our findings
are also likely to have implications for other studies of urgent
investigation for serious conditions.
Ethics and trial registration. NHS ethics was approved by the
North Wales Research Ethics Committee (11/WA/0222) on the
25 August 2011. ClinicalTrials.gov NCT01344005.
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